Loading stock…

Travere Therapeutics, Inc. (TVTX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Travere Therapeutics, Inc.

TVTXMarket cap $5.28BPrice $56.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for rare kidney diseases that most pharma companies ignore because the patient populations are too small to matter. Its drug Filspari became the first oral therapy approved for IgA nephropathy, a disease with almost no options before it.

In Bastion Portfolios?

52W Return+105%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+65%10

Revenue Forecast

Rev CAGR (1y)+48%10

Rev CAGR (3y)+41%10

Rev CAGR (5y)+29%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+283%10

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin-7%1

Net Income Margin-7%1

Free Cash Flow Margin16%7

Debt

Net Debt/EBITDA4.72

Efficiency

ROE-236%1

ROA-6%1

Earnings Stability22

GEAR+WEAK32

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)89

P/BV215.21

EV Multiples

EV/EBITDA Fwd183

EV/EBIT Fwd6661

Yield

Free Cash Flow Yieldna–

Dividend Yieldna–

Momentum

Short term

1 month return-14%1

3 month return-3%5

YTD return+47%9

Mid term

Price vs 52wHigh81%5

1 year return+120%10

Long term

3 year return+637%10

5 year return+115%8

Risk Shield

Price Risk

Beta1.81

Volatility61%2

Free Cash Flow

Free Cash Flow Margin16%7

Free Cash Flow Yieldna–

Quality

ROCE-8%1

Earnings Stability22

Net Debt/EBITDA4.72

02Growth

Is it actually growing, and how fast?

TVTXTravere Therapeutics

Revenue FY25$491M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+65%10

Revenue, next 1Y+48%10

Revenue, next 3Y, CAGR+41%10

Revenue, next 5Y, CAGR+29%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+283%10

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 65%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 41%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 29%/yr over five years.10/10

WATCH

Revenue grew 65%/yr over the last 3 years; forecasts see it cooling to 41%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-14%1

3-month return-3%5

YTD return+47%9

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+120%10

3-year return+637%10

5-year return+115%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +637% over three years and +115% over five, ahead of 80% of the market.

It's up 120% over the past year, but 19% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+47%).

WATCH

Returns sit at the market level over three months (-3%).

WEAKNESSES

The stock is underperforming over the past month (-14%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Travere Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TVTXTravere Therapeutics

Revenue FY25$491M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+65%10

Revenue, next 1Y+48%10

Revenue, next 3Y, CAGR+41%10

Revenue, next 5Y, CAGR+29%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+283%10

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 65%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 41%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 29%/yr over five years.10/10

WATCH

Revenue grew 65%/yr over the last 3 years; forecasts see it cooling to 41%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-14%1

3-month return-3%5

YTD return+47%9

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+120%10

3-year return+637%10

5-year return+115%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +637% over three years and +115% over five, ahead of 80% of the market.

It's up 120% over the past year, but 19% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+47%).

WATCH

Returns sit at the market level over three months (-3%).

WEAKNESSES

The stock is underperforming over the past month (-14%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Travere Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community